Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWing Fai LiKGKira GritsmanDLDavid Levitz

Discussion

Loading...

Member takes

Overview

Real-world evidence shows low-dose HMA-venetoclax reduces costs and hospitalization in AML/MDS, highlighting cost-effectiveness benefits.

Key Points

  • To compare economic outcomes and hospitalization days between low-dose and standard-dose HMA-venetoclax in AML/MDS patients.
  • Analyzed real-world cohorts of AML and MDS patients at MECCC.
  • Constructed a Markov model for treatment outcomes using TreeAge Pro in the study design.
  • Evaluated cost-effectiveness using ICER based on QALYs and total costs across cohorts.
  • MLD HMA-venetoclax showed lower monthly costs of $5,269 versus $19,875 for standard dose.
  • QALYs were significantly higher in MLD (13.17) than in SD (4.86), with an ICER of -$6,598 per QALY, indicating cost dominance.
  • Hospitalization rates were lower in the MLD group, with fewer days and a 39% reduced risk of hospitalization.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0echttps://doi.org/10.1182/blood-2025-4429
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML2025
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025
  4. 4Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia2026 · 1 citations
  5. 5Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations